Aurobindo Pharma Lands In Patent Litigation Cases In USA

Angiomax (bivalirudin) is used as an anticoagulant in patients with unstable angina undergoing percutaneous translurninal coronary angioplasty.

Kowa in its petition filed in District Court of Southern District of New York alleged that Aurobindo's recent ANDA with US Food and Drug Administration would infringe on its patented drug Livalo (Pitavastatin) on four counts.

Pitavastatin is used as an adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and to increase high-density lipoprotein cholesterol.

"Plaintiff request the following relief...a permanent injunction restraining and enjoining against any infringement by defendants...of the Livalo patents, through the commercial manufacture, use, sale, offer for sale or importation into the United States of Aurobindo's pitavastatin drug product or any drug product containing Pitavastatin," Kowa prayed the court in its petition.

Kowa also filed a similar petition against another Indian drug maker Zydus Pharmaceuticals on the same drug.
READ MORE:
India Seeks Crucial Reforms of UN Security Institutions
U.S. Court Dismisses 1984 Riots Case Against Congress